原创力文档- 1、本文档共10页，可阅读全部内容。
- 2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
- 3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
查看更多
Antihemophilic factor plasma albumin free method for the management and prevention of
? 2009 Pipe, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which
permits unrestricted noncommercial use, provided the original work is properly cited.
Biologics: Targets Therapy 2009:3 117–125 117
R E V I E W
Antihemophilic factor (recombinant)
plasma/albumin-free method for the management
and prevention of bleeding episodes in patients
with hemophilia A
Steven Pipe
Department of Pediatrics
and Communicable Diseases, University
of Michigan, Ann Arbor, MI, USA
Correspondence: Steven W Pipe, MD
Department of Pediatrics
and Communicable Diseases, University
of Michigan, 1500 East Medical Center
Drive, Ann Arbor, Michigan 48109, USA
Tel +1 734 647 2893
Fax +1 734 936 7083
Email ummdswp@med.umich.edu
Abstract: Hemophilia is a rare genetic bleeding disorder that, if not adequately controlled, is
associated with life-threatening bleeding events and serious and costly complications, primarily
from joint damage. The advent of effective clotting factor replacement therapy for patients
with hemophilia is considered one of the foremost medical advances of the 20th century. The
last 3 decades of experience in hemophilia care have witnessed the effectiveness of the care
of patients with hemophilia within specialized comprehensive care centers, advances in factor
replacement therapies, the benefi ts of prophylaxis over on-demand replacement therapy, and
the role of aggressive management of joint disease to prevent dysfunction. Ongoing challenges,
including the management of inhibitors to factor therapies and the consequences of thousands
of patients with hemophilia becoming infected with human immunodefi ciency virus and
hepatitis C virus in the 1980s from contaminated plasma-derived factor concentrates, have
highlighted the need for vigilance with respect to clotting factor product safety, access to care,
and a full complement of choice of factor replacement therapies. Advate? (antihemophilic
factor [recombinant] plasma/albu
您可能关注的文档
- A complete passive blind image copy-move forensics scheme based on compound statistics features.pdf
- A continuum damage mechanics model for ductile fracture.pdf
- A CRIME HAS BEEN COMMITTED.pdf
- A DICTIONARY FOR LINEAR ALGEBRA线性代数词典.pdf
- A Formal Modeling Approach for Supply Chain Event Management.pdf
- A Format for Instantons and Their Characterizations.pdf
- A framework for mobile robot concurrent path planning and execution in incomplete and uncer.pdf
- A framework for universal service access using device ensemble.pdf
- A Fusion of GMCSF and IL-21 Initiates.pdf
- A fresh meat almost ideal demand system incorporating negative TV press and advertising impact.pdf
文档评论（0）